LNG Energy Group (OTCMKTS:MCURF) & Hyperion DeFi (NASDAQ:HYPD) Head-To-Head Analysis

LNG Energy Group (OTCMKTS:MCURF) and Hyperion DeFi (NASDAQ:HYPD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares LNG Energy Group and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LNG Energy Group	N/A	N/A	N/A
Hyperion DeFi	N/A	-91.59%	-73.08%

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares LNG Energy Group and Hyperion DeFi”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LNG Energy Group	N/A	N/A	N/A	N/A	N/A
Hyperion DeFi	$810,000.00	65.51	-$45.31 million	($9.95)	-0.35

LNG Energy Group has higher earnings, but lower revenue than Hyperion DeFi.

Analyst Recommendations

This is a summary of recent recommendations for LNG Energy Group and Hyperion DeFi, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LNG Energy Group	0	0	0	0	0.00
Hyperion DeFi	2	0	1	1	2.25

Hyperion DeFi has a consensus target price of $5.88, indicating a potential upside of 67.86%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts clearly believe Hyperion DeFi is more favorable than LNG Energy Group.

Summary

Hyperion DeFi beats LNG Energy Group on 7 of the 9 factors compared between the two stocks.

About LNG Energy Group

Mind Cure Health Inc. engages in the acquisition and development of natural gas production and exploration assets in Latin America. The company was founded in 2008 and is based in Vancouver, Canada.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.